FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrzej Horban

Research Profile

Disorders

Concepts & Ideas

Geographic Areas

Poland

Living Beings

Chemicals & Drugs

Procedures

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Stanislas Pol; Stuart Roberts; Rolf P G van Heeswijk; Zobair Younossi; Stefan Zeuzem; Paul J Pockros; Jeroen Aerssens; Pietro Andreone; Maria Beumont; Martyn Botfield; Sandra De Meyer; Roberto Focaccia; Graham R Foster; Andrzej Horban; Eric J Lawitz; Don Luo; Gaston Picchio
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Patrick Marcellin; Denis Ouzan; Massimo Puoti; Maribel Rodriguez-Torres; Manuela Schmitz; Mitchell L Shiffman; Fernando Tatsch; Hugo Cheinquer; Manuela Curescu; Geoffrey M Dusheiko; Peter Ferenci; Andrzej Horban; Donald Jensen; Gabriella Lengyel; Alessandra Mangia; Mario Rizzetto
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
K Caraballo Cortés; M Fic; Andrzej Horban; T Laskus; A Pawełczyk; Hanna Berak; I Bukowska-Ośko; Marek Radkowski
Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrzej Horban (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stanislas Pol; Stuart Roberts; Rolf P G van Heeswijk; Zobair Younossi; Stefan Zeuzem; Paul J Pockros; Jeroen Aerssens; Pietro Andreone; Maria Beumont; Martyn Botfield; Sandra De Meyer; Roberto Focaccia; Graham R Foster; Andrzej Horban; Eric J Lawitz; Don Luo; Gaston Picchio
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Journal of hepatology 2013;58(5):883-9.
2012: Patrick Marcellin; Denis Ouzan; Massimo Puoti; Maribel Rodriguez-Torres; Manuela Schmitz; Mitchell L Shiffman; Fernando Tatsch; Hugo Cheinquer; Manuela Curescu; Geoffrey M Dusheiko; Peter Ferenci; Andrzej Horban; Donald Jensen; Gabriella Lengyel; Alessandra Mangia; Mario Rizzetto
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Hepatology (Baltimore, Md.) 2012;56(6):2039-50.
2012: K Caraballo Cortés; M Fic; Andrzej Horban; T Laskus; A Pawełczyk; Hanna Berak; I Bukowska-Ośko; Marek Radkowski
Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.
Advances in medical sciences 2012;57(2):370-4.
2012: Joanne Reekie; Jurgen Rockstroh; Andrzej Horban; Anders Karlsson; Igor Karpov; Ole Kirk; Justyna D Kowalska; Jens D Lundgren; Amanda Mocroft; Aza Rakhmanova
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.
PloS one 2012;7(7):e41673.
2011: Robert Flisiak; Waldemar Halota; Andrzej Horban; Jacek Juszczyk; Malgorzata Pawlowska; Krzysztof Simon
Prevalence and risk factors of HCV infection in Poland.
European journal of gastroenterology & hepatology 2011;23(12):1213-7.
2011: Edward J Gane; Andrzej Horban; Isabel Nájera; Regine Rouzier; Pratibha Sampeur; Nancy S Shulman; Patrick Smith; Catherine Stedman; Alicja Wiercinska-Drapalo; Ying Zhang; Linda Chang; Jonathan Q Tran
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Journal of hepatology 2011;55(5):972-9.
2011: Vincent Soriano; Eva Poveda; Jürgen Rockstroh; Francisco Antunes; Antonella d'Arminio Monforte; Stephane de Wit; Daniel Grint; Andrzej Horban; Clifford Leen; Jens Lundgren; Lars Peters
Hepatitis delta in HIV-infected individuals in Europe.
AIDS (London, England) 2011;25(16):1987-92.
2011: Michael Manns; Stefan Mauss; Ismail Merican; Thomas H Müller; Lisa D Pedicone; Martin Rössle; Ajit Sood; Saif Abu-Mouch; Peter Buggisch; Rongdean Chen; Markus Cornberg; Rab Faruqi; Holger Hinrichsen; Andrzej Horban; Yaron Ilan; Hartwig Klinker; Yoav Lurie; Christoph Welsch; Stefan Zeuzem; Heiner Wedemeyer
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Journal of hepatology 2011;55(3):554-63.
2011: Alexey Kruk; Jens D Lundgren; Amanda Mocroft; Daria Podlekareva; Aza G Rakhmanova; Wendy Bannister; Nelly P Chentsova; Perre Domingo; Andrzej Horban; Ole Kirk
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.
AIDS (London, England) 2011;25(12):1505-13.
2011: Stefan Zeuzem; Pietro Andreone; Maria Beumont; Griet Boogaerts; Sandra De Meyer; Moises Diago; Peter Ferenci; Roberto Focaccia; Graham R Foster; Andrzej Horban; Eric J Lawitz; Don Luo; Beat Müllhaupt; Frederik Nevens; Gaston Picchio; Paul Pockros; Stanislas Pol; Ramon Polo; Stuart Roberts; Daniel Shouval; Ruben Terg; Rolf Van Heeswijk; Bart van Hoek; Ola Weiland; Zobair Younossi
Telaprevir for retreatment of HCV infection.
The New England journal of medicine 2011;364(25):2417-28.
2011: Kamila Caraballo Cortés; Maria Fic; Andrzej Horban; Iwona Ośko; Agnieszka Pawełczyk; Hanna Berak; Marek Radkowski
[Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
Przegla̧d epidemiologiczny 2011;65(2):319-24.
2011: Joseph Gathe; Andrzej Horban; Mark Nelson; Thuy Nguyen; Daniel Podzamczer; Jaime Andrade-Villanueva; Johannes Bogner; Pedro Cahn; Murray Drulak; Steven Santiago; David Spencer; Chan-Loi Yong; Wei Zhang; Anne-Marie Quinson
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Antiviral therapy 2011;16(5):759-69.
2011: Marcin Paciorek; Witold Przyjałkowski; Ewa Czekalska-Lachowicz; Dariusz Lipowski; Andrzej Horban
[Listeriosis of the central nervous system: epidemiological and diagnostic aspects--own observations].
Przegla̧d epidemiologiczny 2011;65(1):63-6.
2011: Yun-Fan Liaw; I-Shyan Sheen; Chuan-Mo Lee; Ulus Salih Akarca; George V Papatheodoridis; Florence Suet-Hing Wong; Ting-Tsung Chang; Andrzej Horban; Chia Wang; Peter Kwan; Maria Buti; Martin Prieto; Thomas Berg; Kathryn Kitrinos; Ken Peschell; Elsa Mondou; David Frederick; Franck Rousseau; Eugene R Schiff
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Hepatology (Baltimore, Md.) 2011;53(1):62-72.
2010: David A M C van de Vijver; Jori Symons; B Åsjö; M Bruckova; Ricardo Camacho; Andrzej Horban; M Linka; Marios Lazanas; C Loveday; E MacRae; C Nielsen; Dimitrios Paraskevis; M Poljak; Elisabeth Puchhammer-Stöckl; L Ruiz; J-C Schmit; G Stanczak; M Stanojevic; Anne-Mieke Vandamme; J Vercauteren; Maurizio Zazzi; Lee Bacheler; P Lecocq; Jorge Villacian; L B Jorgensen; Charles A B Boucher
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries.
Acta dermatovenerologica Alpina, Panonica, et Adriatica 2010;19(4):3-9.
2010: Maria Buti; Yoav Lurie; Natalia G Zakharova; Natalia P Blokhina; Andrzej Horban; Gerlinde Teuber; Christoph Sarrazin; Ligita Balciuniene; Saya V Feinman; Rab Faruqi; Lisa Pedicone; Rafael Esteban
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Hepatology (Baltimore, Md.) 2010;52(4):1201-7.
2010: Grzegorz P Stańczak; Janusz J Stańczak; Magdalena Marczyńska; Ewa Firlag-Burkacka; Alicja Wiercińska-Drapało; Magdalena Leszczyszyn-Pynka; Elzbieta Jabłonowska; Ewa Małolepsza; Tomasz Dyda; Piotr Zabek; Andrzej Horban
Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008.
Journal of medical virology 2010;82(7):1291-4.
2010: David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin DeJesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna van der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
The Journal of infectious diseases 2010;201(6):803-13.
2010: Jose R Arribas; Andrzej Horban; Jan Gerstoft; Gerdt Fätkenheuer; Mark Nelson; Nathan Clumeck; Federico Pulido; Andrew Hill; Yvon van Delft; Thomas Stark; Christiane Moecklinghoff
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
AIDS (London, England) 2010;24(2):223-30.
2010: Anna Kołakowska-Rzadzka; Hanna Berak; Janusz Stańczak; Tomasz Dyda; Andrzej Horban
Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.
Przegla̧d epidemiologiczny 2010;64(1):69-71.
2010: Grazyna Cholewińska; Józef Higersberger; Regina Podlasin; Alicja Wiercińska-Drapało; Dariusz Lipowski; Maria Olszyńska-Krowicka; Witold Przyjałkowski; Andrzej Horban
[Influence of concomitant illness on clinical manifestations and severity of A/H1N1 influenza infection among patients hospitalized in the Hospital of Infectious Diseases in Warsaw--clinical cases].
Przegla̧d epidemiologiczny 2010;64(1):21-5.
2010: Grazyna Cholewińska; Józef Higersberger; Regina Podlasin; Alicja Wiercińska-Drapało; Dariusz Lipowski; Maria Olszyńska-Krowicka; Witold Przyjałkowski; Andrzej Horban
[Clinical manifestations, diagnosis and treatment of swine flu (A/H1N1) infection among patients hospitalized in the Hospital of Infectious Diseases in Warsaw in 2009].
Przegla̧d epidemiologiczny 2010;64(1):15-9.
2009: Alessandro Cozzi-Lepri; Andrew N Phillips; Javier Martinez-Picado; Antonella d'Arminio Monforte; Christine Katlama; Ann-Brit Eg Hansen; Andrzej Horban; Johann Bruun; Bonaventura Clotet; Jens D Lundgren
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
The Journal of infectious diseases 2009;200(5):687-97.
2009: Robert Flisiak; Saya V Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryczka; Małgorzata Pawlowska; Jenny E Heathcote; Giuseppe Mazzella; Carmen Vandelli; Valérie Nicolas-Métral; Pierre Grosgurin; Jorge S Liz; Pietro Scalfaro; Hervé Porchet; Raf Crabbé
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.
Hepatology (Baltimore, Md.) 2009;49(5):1460-8.
2009: Tomasz Niemiec; Jan Kotarski; Sanisław Radowicki; Andrzej Horban; Magdalena Marczyńska; Romuald Debski
[Recommendations of an expert group appointed by the Polish Gynaecological Society on Prevention of Mother-to-Child Transmission of HIV].
Ginekologia polska 2009;80(1):59-62.
2009: Philippe Flandre; Constance Delaugerre; Jade Ghosn; Marie Laure Chaix; Andrzej Horban; Pierre-Marie Girard; Andrzej Gladysz; Isabelle Cohen-Codar; Philippe Ngo Van; Anne-Marie Taburet; Christine Rouzioux; Jean-François Delfraissy
Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
Antiviral therapy 2009;14(1):93-7.
2008: Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer
Maraviroc for previously treated patients with R5 HIV-1 infection.
The New England journal of medicine 2008;359(14):1429-41.
2008: Robert Flisiak; Andrzej Horban; Philippe Gallay; Michael Bobardt; Suganya Selvarajah; Alicja Wiercinska-Drapalo; Ewa Siwak; Iwona Cielniak; Jozef Higersberger; Jarek Kierkus; Christian Aeschlimann; Pierre Grosgurin; Valérie Nicolas-Métral; Jean-Maurice Dumont; Hervé Porchet; Raf Crabbé; Pietro Scalfaro
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
Hepatology (Baltimore, Md.) 2008;47(3):817-26.
2008: Jean-François Delfraissy; Philippe Flandre; Constance Delaugerre; Jade Ghosn; Andrzej Horban; Pierre-Marie Girard; Michael Norton; Christine Rouzioux; Anne-Marie Taburet; Isabelle Cohen-Codar; Philippe Ngo Van; Jean-Pierre Chauvin
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
AIDS (London, England) 2008;22(3):385-93.
2008: Tomasz Pawiński; Piotr Pulik; Beata Gralak; Andrzej Horban
Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.
Acta poloniae pharmaceutica 2008;65(1):93-100.
2008: Amanda Mocroft; Andrzej Horban; Bonaventura Clotet; Antonella d'Arminio Monforte; J R Bogner; P Aldins; T Staub; Francisco Antunes; Christine Katlama; Jens D Lundgren
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
HIV medicine 2008;9(1):41-6.
2007: José M Gatell; Dominique Salmon-Ceron; Adriano Lazzarin; Eric Van Wijngaerden; Francisco Antunes; Clifford Leen; Andrzej Horban; Victoria Wirtz; Linda Odeshoo; Monique Van den Dungen; Claudia Gruber; Emilio Ledesma
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1484-92.
2007: Agnieszka Bednarska; Andrzej Horban; Marek Radkowski
Central nervous system as a possible site of HCV replication.
Przegla̧d epidemiologiczny 2007;61(4):739-45.
2007: Justyna Dominika Kowalska; Ewa Firlag-Burkacka; Małgorzata Niezabitowska; Andrzej Horban
[Factors influencing time from exposure to post-exposure prophylaxis of HIV infection in patients consulted in 2001-2004 in out-patient clinic of Hospital for Infectious Diseases in Warsaw].
Przegla̧d epidemiologiczny 2007;61(2):357-62.
2007: Grzegorz Piotr Stańczak; Janusz Julian Stańczak; Ewa Firlag-Burkacka; Alicja Wiercińska-Drapało; Magdalena Leszczyszyn-Pynkad; Ewa Jabłonowska; Ewa Małolepsza; Andrzej Horban
[Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland].
Przegla̧d epidemiologiczny 2007;61(1):29-34.
2006: Regina Podlasin; Alicja Wiercinska-Drapalo; A Olczak; Marek Beniowski; T Smiatacz; Ewa Malolepsza; Jacek Juszczyk; M Leszczyszyn-Pynka; Tomasz Mach; M Mian; B Knysz; Andrzej Horban
Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
Infection 2006;34(4):196-200.
2006: J Gold; M J Batterham; H Rekers; M K Harms; T B P Geurts; P M E Helmyr; J Silva de Mendonça; L H Falleiros Carvalho; George Panos; A Pinchera; Fernando Aiuti; C Lee; Andrzej Horban; José M Gatell; Praphan Phanuphak; Wisit Prasithsirikul; B Gazzard; M Bloch; S A Danner
Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
HIV medicine 2006;7(3):146-55.
2006: Justyna Dominika Kowalska; Ewa Firlag-Burkacka; Małgorzata Niezabitowska; Elzbieta Bakowska; Anna Ignatowska; Piotr Pulik; Andrzej Horban
[Post-exposure prophylaxis of HIV infection in out-patient clinic of hospital for infectious diseases in Warsaw in 2001-2002].
Przegla̧d epidemiologiczny 2006;60(4):789-94.
2006: Hanna Berak; Anna Kołakowska-Rzadzka; Marek Wasilewski; Janusz J Stańczak; Bardadin Krzysztof; Bozena Walewska-Zielecka; Andrzej Horban
[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].
Przegla̧d epidemiologiczny 2006;60(4):673-6.
2006: Andrzej Horban; Marek Wasilewski; Hanna Berak; Janusz J Stańczak; Krzysztof Bardadin; Hanna Paprocka
[Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C].
Przegla̧d epidemiologiczny 2006;60(3):563-9.
2006: Hanna Berak; Marek Wasilewski; Andrzej Horban; Janusz J Stańczak; Aneta Cybula
[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (+)].
Przegla̧d epidemiologiczny 2006;60(2):253-7.
2006: Hanna Berak; Marek Wasilewski; Andrzej Horban; Janusz J Stańczak; Aneta Cybula
[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].
Przegla̧d epidemiologiczny 2006;60(2):247-51.
2005: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; bruno ledergerber; Jens Lundgren
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
The Journal of infectious diseases 2005;192(6):992-1002.
2005: Marek Radkowski; Andrzej Horban; Juan F Gallegos-Orozco; Agnieszka Pawelczyk; Joanna Jablonska; Jeffrey Wilkinson; Debra Adair; Tomasz Laskus
Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels.
The Journal of infectious diseases 2005;191(10):1730-3.
2005: Christian Holkmann Olsen; José M Gatell; bruno ledergerber; Christine Katlama; Nina Friis-Møller; Jonathan Weber; Andrzej Horban; Schlomo Staszewski; Jens D Lundgren; Andrew N Phillips
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
AIDS (London, England) 2005;19(3):319-30.
2005: Agnieszka Bednarska; Regina Podlasin; Grzegorz Karczewski; Teresa Loch; Andrzej Horban; Marek Radkowski
[Utility of multiplex PCR for diagnosis of neurological disorders in HIV-infected patients and patients with AIDS].
Przegla̧d epidemiologiczny 2005;59(4):873-9.
2005: Janusz Cianciara; Joanna Jabłońska; Andrzej Horban; Bozena Walewska-Zielecka
[Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].
Przegla̧d epidemiologiczny 2005;59(2):385-94.
2004: Amanda Mocroft; bruno ledergerber; Jean-Paul Viard; Schlomo Staszewski; M Murphy; Antonio Chiesi; Andrzej Horban; Ann-Brit Eg Hansen; Andrew N Phillips; Jens D Lundgren
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
The Journal of infectious diseases 2004;190(11):1947-56.
2004: Frank van Leth; Praphan Phanuphak; Erik S G Stroes; Brian Gazzard; Pedro Cahn; François Raffi; Robin Wood; Mark Bloch; Christine Katlama; John J P Kastelein; Mauro Schechter; Robert L Murphy; Andrzej Horban; David B Hall; Joep M A Lange; Peter Reiss
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: Andrew N Phillips; bruno ledergerber; Andrzej Horban; Peter Reiss; Antonio Chiesi; Ole Kirk; Fiona Mulchany; Martin Fisher; Ladislav Machala; Jens D Lundgren
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
AIDS (London, England) 2004;18(13):1795-804.
2004: Ulrik B Dragsted; Amanda Mocroft; STEFANO VELLA; Jean-Paul Viard; Ann-Brit Eg Hansen; George Panos; Danielle Mercey; Ladislav Machala; Andrzej Horban; Jens D Lundgren
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
The Journal of infectious diseases 2004;190(1):148-55.
2004: Frank van Leth; Praphan Phanuphak; Kiat Ruxrungtham; Ezio Baraldi; S Miller; B Gazzard; Pedro Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; Robin Wood; G C Levi; G Reboredo; Kathleen E Squires; Isabel Cassetti; D Petit; F Raffi; Christine Katlama; Robert L Murphy; Andrzej Horban; J P Dam; Elly A M Hassink; Remko van Leeuwen; P Robinson; Ferdinand W N M Wit; Joep M A Lange
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Lancet 2004;363(9417):1253-63.
2004: Daniel H Blanckenberg; Robin Wood; Andrzej Horban; Marek Beniowski; Anna Boron-Kaczmarska; Hanna Trocha; Waldemar Halota; Reinhold E Schmidt; G Fatkenheuer; Heiko Jessen; Joep M A Lange
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
AIDS (London, England) 2004;18(4):631-40.
2004: Marek Radkowski; Agnieszka Bednarska; Andrzej Horban; Janusz J Stanczak; Jeffrey Wilkinson; Debra Adair; Marek Nowicki; Jorge Rakela; Tomasz Laskus
Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8.
The Journal of general virology 2004;85(Pt 1):47-59.
2003: Remko van Leeuwen; Christine Katlama; Robert L Murphy; Kathleen E Squires; José M Gatell; Andrzej Horban; Bonaventura Clotet; Shlomo Staszewski; Arne van Eeden; Nathan Clumeck; Mauro Moroni; Andrew T Pavia; Reinhold E Schmidt; Juan Gonzalez-Lahoz; Julio Montaner; Francisco Antunes; Roy M Gulick; Dénes Bánhegyi; Marc van der Valk; Peter Reiss; Liesbeth van Weert; Frank van Leth; Victoria A Johnson; Jean-Pierre Sommadossi; Joep M A Lange
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2002: Andrzej Horban; Janusz J Stanczak; Elzbieta Bakowska; E J Tobolewska; K J Przybylska-Stengiel; G P Stanczak; E Burkacka
High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
Infection 2002;30(6):356-9.
2002: Timothy W Schacker; Phuong L Nguyen; Esteban Martinez; Cavan Reilly; José M Gatell; Andrzej Horban; Elzbieta Bakowska; Baiba Berzins; Remko van Leeuwen; Steven Wolinsky; Ashley T Haase; Robert L Murphy
Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy.
The Journal of infectious diseases 2002;186(8):1092-7.
2001: Ferdinand W N M Wit; Robin Wood; Andrzej Horban; Marek Beniowski; Reinhold E Schmidt; Glenda Gray; Adriano Lazzarin; A Lafeuillade; D Paes; Hilde Carlier; L van Weert; C de Vries; Remko van Leeuwen; Joep M A Lange
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
AIDS (London, England) 2001;15(18):2423-9.
2001: Marc van der Valk; John J P Kastelein; Robert L Murphy; Frank van Leth; Christine Katlama; Andrzej Horban; M Glesby; G Behrens; Bonaventura Clotet; R K Stellato; H O Molhuizen; Peter Reiss
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: E Gołab; A Sobolewska; Elzbieta Bitkowska; Agnieszka Bednarska; Hanna Berak; T H Dzbeński; Andrzej Horban
[Nested PCR in the diagnosis of Pneumocystis carinii pneumonia (PCP) in AIDS patients].
Wiadomości parazytologiczne 2001;47(3):521-5.
2001: N Zalewska-Schönthaler; J Schönthaler-Humiecka; Regina Podlasin; G Cholewińska; T Rzeszkowicz; T Mikuła; Andrzej Horban
[Tuberculosis and mycobacteriosis important opportunistic disease in AIDS patients].
Przegla̧d epidemiologiczny 2001;55 Suppl 3():117-25.
2000: Tomasz Laskus; Marek Radkowski; Andrzej Piasek; Marek Nowicki; Andrzej Horban; Janusz Cianciara; Jorge Rakela
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes.
The Journal of infectious diseases 2000;181(2):442-8.
1999: J J Stańczak; J Opoka-Kegler; M Czerwionka-Szaflarska; K Karczewska; T Woźniakowska-Gesicka; Andrzej Horban
Distribution of hepatitis C virus genotypes in Poland.
Journal of hepatology 1999;31(3):574.
1998: K T Niemiec; Andrzej Horban; B Chazan; Ewa Firlag-Burkacka
[Antiretroviral therapy in pregnant women with HIV].
Ginekologia polska 1998;69(11):820-6.
1998: H Swiderska; J Nitkiewicz; A Piwowarska; M Jończyk; G Cholewińska; D Tomaszewska; Andrzej Horban
[Humoral response to HBV antigens in acute and chronic hepatitis B].
Przegla̧d epidemiologiczny 1998;52(4):469-81.
1997: J J Stańczak; J Opoka-Kegler; Andrzej Lipniacki; J Baran; Andrzej Piasek; Andrzej Horban
Peripheral blood mononuclear cell-based system for monitoring interferon therapy for hepatitis C virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(3):746-7.
1996: Marek Radkowski; M Sadowska; E Kopicz-Kamińska; Andrzej Horban; J Slusarczyk
[Coexpression of CD4 and CD8 antigens and the appearance of HLA-DR and CD25 receptors on lymphocytes as markers of immune activation in patients with HIV infection].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 1996;1(5):325-6.
1996: Marek Radkowski; E Kopicz-Kamińska; T Werezyńska; Andrzej Horban; J Slusarczyk
[Presence of autoantibodies in patients infected with HIV].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 1996;1(4):254-6.
1996: A Zieliński; G Cholewińska; B Wondołowska; E Bakowska; E Kopicz-Kamińska; J Zajaczkowska; N Zalewska-Schonthaler; J Baran; A Lipniacki; W Woźny; Andrzej Horban; E Burkacka
[Initial assessment of the use of polymerase chain reaction (PCR) in diagnosis of tuberculosis among patients of the Center for Diagnosis and Treatment of AIDS].
Przegla̧d epidemiologiczny 1996;50(4):401-5.
1996: A Zieliński; G Cholewińska; B Wondołowska; E Bakowska; E Kopicz-Kamińska; E Burkacka; N Zalewska-Schonthaler; J Baran; A Lipniacki; W Woźny; Andrzej Horban
[Initial evaluation of the diagnostic usefulness of tuberculin tests among the patients of the Center of Diagnosis and Treatment of AIDS].
Przegla̧d epidemiologiczny 1996;50(4):395-400.
1992: Tomasz Laskus; Marek Radkowski; E Lupa; Andrzej Horban; Janusz Cianciara; J Slusarczyk
Prevalence of markers of hepatitis viruses in out-patient alcoholics.
Journal of hepatology 1992;15(1-2):174-8.
1992: Tomasz Laskus; Marek Radkowski; T Werezyńska; Andrzej Horban; E Lupa; Janusz Cianciara; J Slusarczyk
[Markers of HBV infection in drug addicts].
Polskie Archiwum Medycyny Wewnętrznej 1992;87(2):104-11.
1992: Tomasz Laskus; Marek Radkowski; E Lupa; Janusz Cianciara; J Slusarczyk; G Halama; Andrzej Horban
Introduction of hepatitis delta virus into Polish drug community.
Infection 1992;20(1):43-4.
1992: Tomasz Laskus; Marek Radkowski; T Werezyńska; Andrzej Horban; E Lupa; Janusz Cianciara; J Slusarczyk
[Occurrence of antibodies against hepatitis C virus (HCV) among drug addicts].
Polskie Archiwum Medycyny Wewnętrznej 1992;87(1):8-13.
1991: Tomasz Laskus; Marek Radkowski; E Lupa; Janusz Cianciara; J Slusarczyk; G Halama; Andrzej Horban
Hepatitis C virus antibody in Poland.
Scandinavian journal of infectious diseases 1991;23(3):385-6.
1988: Z Dziubek; Andrzej Horban; H Zarnowska; J Powałowska; M Baka; M Olszyńska
[Cutaneous leishmaniasis among the cases of the Institute of Infectious and Parasitic Diseases, Medical Academy, in Warsaw].
Wiadomości parazytologiczne 1988;34(4-6):663-4.
1986: Andrzej Horban; G Cholewińska; M Baka; J Brzozowska; Z Dziubek; S Suchecki
[Evaluation of the usefulness of routine serologic tests in the diagnosis of human brucellosis in the current epidemiologic situation].
Przegla̧d epidemiologiczny 1986;40(4):376-80.